心房颤动合并稳定型冠心病患者的抗血栓治疗
AFIRE多中心开放标签随机试验纳入2236例房颤合并稳定型冠心病患者(PCI或CABG术后>1年或血管造影证实无需血运重建),比较利伐沙班单药与利伐沙班联合单一抗血小板药。主要疗效终点(卒中、系统性栓塞、心肌梗死、需血运重建的不稳定型心绞痛或全因死亡)单药组4.14%/患者年 vs 联合组5.75%/患者年(HR 0.72,95%CI 0.55-0.95,非劣效P<0.001)。主要安全终点大出血单药组1.62%/患者年 vs 联合组2.76%/患者年(HR 0.59,95%CI 0.39-0.89,优效P=0.01)。因联合治疗组死亡率增加,试验提前终止。
要点
- 房颤合并稳定型冠心病(PCI/CABG术后>1年或无需血运重建),利伐沙班单药主要疗效终点事件率4.14%/患者年 vs 联合抗血小板5.75%/患者年(HR 0.72,95%CI 0.55-0.95),非劣效。
- 同人群利伐沙班单药大出血事件率1.62%/患者年 vs 联合抗血小板2.76%/患者年(HR 0.59,95%CI 0.39-0.89),单药优效。
- 试验因联合治疗组死亡率增加而提前终止,提示稳定期联合抗血小板策略可能有害。
- 主要疗效终点为卒中、系统性栓塞、心肌梗死、需血运重建的不稳定型心绞痛或全因死亡的复合终点。
适用人群与场景
- 房颤合并稳定型冠心病患者:既往PCI或CABG术后超过1年,或血管造影证实冠心病无需血运重建。
处置流程与药物剂量
- 利伐沙班单药治疗:非维生素K拮抗剂口服抗凝药单药,不联合抗血小板药。
- 联合治疗:利伐沙班加单一抗血小板药。
研究设计与关键结果
- 多中心、开放标签随机试验,纳入2236例房颤合并稳定型冠心病患者,随机接受利伐沙班单药或利伐沙班联合单一抗血小板药。
- 主要疗效终点(卒中、系统性栓塞、心肌梗死、需血运重建的不稳定型心绞痛或全因死亡)单药组4.14%/患者年 vs 联合组5.75%/患者年,HR 0.72(95%CI 0.55-0.95),非劣效P<0.001。
- 主要安全终点大出血(国际血栓与止血学会标准)单药组1.62%/患者年 vs 联合组2.76%/患者年,HR 0.59(95%CI 0.39-0.89),优效P=0.01。
- 试验因联合治疗组死亡率增加而提前终止。
证据类型、等级与局限
- 证据类型:多中心、开放标签随机对照试验(RCT)。
- 试验提前终止,原因为联合治疗组死亡率增加。
对床旁实践的改变
- 对于房颤合并稳定型冠心病(PCI/CABG术后>1年或无需血运重建)患者,利伐沙班单药抗凝在疗效上非劣于联合抗血小板治疗,且大出血更少。
- 联合抗血小板治疗组死亡率增加,提示在稳定期应避免常规联合抗血小板治疗。
指南或共识出处
- AFIRE试验(UMIN000016612;NCT02642419),由日本心血管研究基金会资助。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: There are limited data from randomized trials evaluating the use of antithrombotic therapy in patients with atrial fibrillation and stable coronary artery disease.
METHODS: In a multicenter, open-label trial conducted in Japan, we randomly assigned 2236 patients with atrial fibrillation who had undergone percutaneous coronary intervention (PCI) or coronary-artery bypass grafting (CABG) more than 1 year earlier or who had angiographically confirmed coronary artery disease not requiring revascularization to receive monotherapy with rivaroxaban (a non-vitamin K antagonist oral anticoagulant) or combination therapy with rivaroxaban plus a single antiplatelet agent. The primary efficacy end point was a composite of stroke, systemic embolism, myocardial infarction, unstable angina requiring revascularization, or death from any cause; this end point was analyzed for noninferiority with a noninferiority margin of 1.46. The primary safety end point was major bleeding, according to the criteria of the International Society on Thrombosis and Hemostasis; this end point was analyzed for superiority.
RESULTS: The trial was stopped early because of increased mortality in the combination-therapy group. Rivaroxaban monotherapy was noninferior to combination therapy for the primary efficacy end point, with event rates of 4.14% and 5.75% per patient-year, respectively (hazard ratio, 0.72; 95% confidence interval [CI], 0.55 to 0.95; P<0.001 for noninferiority). Rivaroxaban monotherapy was superior to combination therapy for the primary safety end point, with event rates of 1.62% and 2.76% per patient-year, respectively (hazard ratio, 0.59; 95% CI, 0.39 to 0.89; P = 0.01 for superiority).
CONCLUSIONS: As antithrombotic therapy, rivaroxaban monotherapy was noninferior to combination therapy for efficacy and superior for safety in patients with atrial fibrillation and stable coronary artery disease. (Funded by the Japan Cardiovascular Research Foundation; AFIRE UMIN Clinical Trials Registry number, UMIN000016612; and ClinicalTrials.gov number, NCT02642419.).
参考来源
- Yasuda S, Kaikita K, Akao M, et al. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. N Engl J Med. 2019. PMID: 31475793. doi:10.1056/NEJMoa1904143
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。